NCT05563454View on ClinicalTrials.gov

A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 11, 2022

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
Diabetic Neuropathic PainHealthy Volunteers
Interventions
DRUG

BAY2395840

Administration of dosage form 1 under diet 1 condition

Trial Locations (1)

813-0017

SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05563454 - A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants | Biotech Hunter | Biotech Hunter